Neovasc (NSDQ:NVCN) today priced an upcoming offering looking to raise $5 million to support its Tiara and Reducer devices. In the round, the Vancouver-based company will look to float approximately 11.1 million shares of its common stock at a price of 45¢ per share. The offering is expected to close on March 15, the company said. […]
Neovasc advances warrant exchange from CardiAQ case
Neovasc (NSDQ:NVCN) said today that it inked an exchange deal for the last of the warrants it issued as part of a $65 million funding round to cover the damages from litigation with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve. The Vancouver-based replacement heart valve developer said it plans to exchange the Series A and Series E warrants it […]
Neovasc prices $5m offering
Neovasc (NSDQ:NVCN) today priced a $5 million offering of its common stock slated to support its Reducer device and Tiara transcatheter mitral valve. The Vancouver-based company said it plans to float approximately 11.1 million shares of its common stock at a price of 45¢ per share, expecting to bring in approximately $5 million in gross proceeds. […]
Neovasc inks $3m settlement deal with MID, raises $1m
Neovasc (NSDQ:NVCN) said today that it inked a $3 million settlement agreement with Micro Interventional Devices to resolve undisclosed allegations related to Neovasc’s transcatheter mitral valve replacement technology, including its flagship Tiara device, and added that it has raised approximately $1.2 million. The agreement includes payments totally approximately $3 million to be made by Neovasc to […]
Neovasc jumps on Tiara trial news
Neovasc (NSDQ:NVCN) said today that it won approval to advance a clinical trial for its Tiara transcatheter mitral valve replacement, sending its share price up on Wall Street. The Vancouver-based company said it closed out the Phase I requirements for the 115-patient Tiara-II trial in the U.K. and Germany, after several reviews. The Clinical Events Committee […]
Neovasc touts Reducer study
Neovasc (NSDQ:NVCN) this week touted a newly-published article that described the use of dipyridamole stress perfusion cardiac magnetic resonance to evaluate its Reducer device. The Vancouver-based company’s device is designed to treat refractory angina. The article, published in the Journal of the American College of Cardiology: Cardiovascular Interventions, featured a 66 year old man with angina who […]
Edwards Lifesciences settlement with Boston Scientific lets Neovasc off the hook
Last week’s legal win for Boston Scientific (NYSE:BSX) in its years-long patent battle with Edwards Lifesciences (NYSE:EW) was also a win for Neovasc (NSDQ:NVCN), that company said today. As part of a settlement deal worked out between Irvine, Calif.-based Edwards and Marlborough, Mass.-based Boston Scientific, the Federal Court of Canada dismissed a lawsuit brought by Edwards against Boston, […]
Neovasc dives on Q3 bottom-line miss
Neovasc (NSDQ:NVCN) shares took a hit this morning after the cardiac device maker missed expectations for its third-quarter losses. Vancouver-based Neovasc, which makes the Reducer refractory angina device and the Tiara transcatheter mitral valve replacement, said its losses grew 122.3% to -$12.9 million, or -70¢ per share, as sales fell -65.0% to $480,540 for the three […]
Neovasc touts Tiara TMVR success rate in study
A small study of the Neovasc (NSDQ:NVCN) Tiara transcatheter mitral valve replacement (TMVR) in high-risk patients revealed a 100% procedural success rate and immediate elimination of mitral regurgitation. Published in Circulation: Cardiovascular Interventions, the study also showed no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days. The twelve patients in the study […]
NeoVasc shares jump on 12-week Reducer data
Neovasc (NSDQ:NVCN) today saw shares jump after it released 12-week data from the first patient implanted with its Reducer device designed for treating refractory angina. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in […]
Neovasc sets date for 1-for-100 reverse split
Neovasc (NSDQ:NVCN) said yesterday it will initiate a 1-for-100 reverse stock split on Friday as it looks to meet the Nasdaq stock market’s minimum bid price requirement. Through the split, the Vancouver-based company will put a single share of its common stock into the hands of each shareholder for every 100 shares they currently possess. The […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube